Follow the Camp4 Therapeutics Corp stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Market capitalisation: €179.1m. The latest transaction was filed on 5 August 2026 (Acquisition). Among the most active insiders: 5AM Partners VI, LLC. The full history is openly available.
25
Insider Decl.
n/a
Thresholds
€16m
12 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Camp4 Therapeutics Corp Strong Buy (bullish), based on 6 analysts. Average price target: US$8.58.
52Σ signal
Buys €16mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
909,090 shares@ US$11.00100.0% of flowCommon StockSEC:0001415889-24-025140:2
Canonical exit: 13 Jan 2025 (T+90)
25 of 25 declarations
About Camp4 Therapeutics Corp
Camp4 Therapeutics Corp is a company focused on developing innovative therapies for genetic diseases. It employs genome editing approaches to create therapeutic solutions.